Array shares surge as PhIII sets the stage for FDA filing; FDA gives Avadel priority review
→ Shares of Array BioPharma $ARRY did some bobbing and weaving on Tuesday, but ended the day up 23% on positive late-stage data from …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
